novo nordisk semaglutide products and competitors is suing Hims & Hers to halt obesity drug copycats Wegovy and Ozempic maker forecasts
Description
Keep your eyes peeled for: Proposed rule changes: There was a proposal to reinterpret the Medicare exclusion for anti-obesity drugs so that obesity itself (not just when comorbid with another condition) might be considered a medically accepted indication. But that change was not finalized in April 2025
It's like having a dynamic duo working overtime to keep your hunger in check and your blood sugar stable
A., Erwin, J
Researchers combining retatrutide with recovery peptides should be especially attentive to nutritional adequacy and may benefit from stacking protocols that account for timing and injection scheduling
A video was also provided in Obesity Matters input
